However, important limitations exist in the current evidence: Most studies have been relatively small with short follow-up periods Many participants had concurrent obesity, making it difficult to separate weight loss effects from direct effects on binge eating behaviour Long-term efficacy and safety data specifically for binge eating disorder are lacking The psychological and behavioural components of BED may require interventions beyond pharmacological appetite suppression There is no official link established by regulatory bodies between GLP-1 agonists and binge eating disorder treatment
By increasing dopamine levels, tesofensine may promote a positive mood state and reduce feelings of sadness, hopelessness, and anxiety
Key Results 14,225 procedures (20072020)
Knapp dahinter teilen sich Daniela Rohrsdorfer mit BEFLGELT und Manfred Dipolt mit ABTEI SENANQUE den 2
doi: 10.1007/s13399-022-03190-w 277 YiC.HuangS.ZhangW.GuoL.XiaT.HuangF.et al
Explore detailed drug insights and clinical data at www.clival.com #GLP1 #DiabetesCare #ObesityTreatment #PharmaInsights #DrugDatabase #ClivalDatabase To view or add a comment, sign in Is this the turning point for obesity management weve been waiting for